Avalo Therapeutics, Inc. (AVTX) P/S ratio

P/S ratio today
1619.9×

Avalo Therapeutics, Inc. (AVTX) trades at 1619.9× its revenue per share for fiscal 2025. At the end of fiscal 2024 (December 31, 2024) its P/S ratio was 126.3×. That is 9515.0% higher than the 1.3× of fiscal 2023. Figures as of 18 Nov 2026, 05:23 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/S ratio today
1619.9×
P/S ratio, fiscal 2024
126.3×
Change on fiscal 2023
+9515.0%
Highest on record
126.3×fiscal 2024
Lowest on record
1.3×fiscal 2023
Fiscal years on record
62016–2024

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Avalo Therapeutics, Inc. P/S ratio, in more detail

Today's figure is 1182.6% above the fiscal 2024 year-end.

Across the 6 fiscal year-ends on record (2016–2024), the highest was 126.3× in fiscal 2024 and the lowest 1.3× in fiscal 2023. Today's P/S ratio is above every one of the 6 fiscal year-ends on record; their median is 4.7×.

History · 6 fiscal years

P/S ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Avalo Therapeutics, Inc. P/S ratio, year by year

Avalo Therapeutics, Inc. (AVTX) P/S ratio by fiscal year
Fiscal yearP/S ratioChangeYear endedShare price at year-endRevenue per share
Today1619.9×—$7.13—
2025——$18.16$0.00
2024126.3× 9,515.0% up$7.43$0.06
20231.3× 50.0% down$9.10$6.93
20222.6×—$1,209.60$460.70
2021——$4,896.00—
2020——$7,603.20—
2019——$15,523.20—
201816.0× 640.6% up$9,302.40$582.10
20172.2× 68.0% down$9,216.00$4,271.00
20166.7×—$2,534.40$376.04
2015——$9,648.00—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

How to read it

It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.

More on AVTX

Avalo Therapeutics, Inc., figure by figure

Avalo Therapeutics, Inc. (AVTX) overview: price, valuation and scorecard

Avalo Therapeutics, Inc. P/S ratio: questions and answers

What is Avalo Therapeutics, Inc.'s P/S ratio?

Avalo Therapeutics, Inc. (AVTX) trades at 1619.9× its revenue per share for fiscal 2025. At the end of fiscal 2024 (December 31, 2024) its P/S ratio was 126.3×. That is 9515.0% higher than the 1.3× of fiscal 2023.

Is Avalo Therapeutics, Inc.'s P/S ratio high or low compared with its own history?

Today's P/S ratio is above every one of the 6 fiscal year-ends on record; their median is 4.7×.

What are the highest and lowest P/S ratio figures on record for Avalo Therapeutics, Inc.?

Across the 6 fiscal year-ends on record (2016–2024), the highest was 126.3× in fiscal 2024 and the lowest 1.3× in fiscal 2023.

How is Avalo Therapeutics, Inc.'s P/S ratio calculated?

The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Avalo Therapeutics, Inc. (AVTX) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/AVTX/ps-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.